SCHEMBL133646

SCHEMBL133646

O=C(O)c1cc(/N=N/c2ccc([N+](=O)[O-])cc2)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 6/20 1.00
ALDH1A1 P00352 6/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
MEN1 O00255 6/20 0.70
KMT2A Q03164 6/20 0.70
HTT P42858 2/20 0.70
BLVRB P30043 2/20 0.70
PDE4A P27815 1/20 0.70
KDR P35968 1/20 0.70
RECQL P46063 2/20 0.67
BLM P54132 2/20 0.67
APP P05067 1/20 0.67
THRB P10828 1/20 0.67
PHLPP2 Q6ZVD8 4/20 0.62
CYP2C9 P11712 2/20 0.62
PTGS1 P23219 1/20 0.62
PTGS2 P35354 1/20 0.62
HSD17B10 Q99714 1/20 0.62
TSHR P16473 2/20 0.58
CYP2D6 P10635 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29359461 1.00 TDP1 (1.00) TDP1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL133647 1.00 TDP1 (1.00) TDP1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL7033973 0.98 TDP1 (0.97) TDP1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL7033980 0.98 TDP1 (0.97) TDP1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL7033984 0.98 TDP1 (0.97) TDP1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3101571 0.88 ALDH1A1 (0.78) TDP1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3101576 0.88 ALDH1A1 (0.78) TDP1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL29481568 0.87 ALDH1A1 (0.77) TDP1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4047509 0.87 ALDH1A1 (0.77) TDP1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4051923 0.87 ALDH1A1 (0.77) TDP1ALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 571 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3757168-B1 ROOM-TEMPERATURE-CURABLE ORGANOPOLYSILOXANE COMPOSITION, STRUCTURE, AND METHOD FOR ASSESSING CURED STATE OF SAID COMPOSITION SHINETSU CHEMICAL CO (JP) 2025-03-26 EP claimed
US-20250092439-A1 LYOPHILISED NUCLEIC ACID AMPLIFICATION REACTION COMPOSITION IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2025-03-20 US claimed
US-20250065568-A1 METHOD, APPARATUS, AND SYSTEM FOR SUPPORT MATERIAL REMOVAL FROM A 3D-PRINTED OBJECT ORYX ADDITIVE INC (US) 2025-02-27 US claimed
US-20250042781-A1 ECO-FRIENDLY METHOD, APPARATUS, AND SYSTEM FOR PRECIPITATION AND COLLECTION OF DISSOLVED SUPPORT MATERIAL ORYX ADDITIVE INC (US) 2025-02-06 US claimed
EP-4463564-A1 LYOPHILISED NUCLEIC ACID AMPLIFICATION REACTION COMPOSITION Imperial College Innovations Limited (GB) 2024-11-20 EP claimed
EP-4444531-A1 METHOD, APPARATUS, AND SYSTEM FOR SUPPORT MATERIAL REMOVAL FROM A 3D-PRINTED OBJECT Oryx Additive, Inc. (US) 2024-10-16 EP claimed
EP-4444546-A1 ECO-FRIENDLY METHOD, APPARATUS, AND SYSTEM FOR PRECIPITATION AND COLLECTION OF DISSOLVED SUPPORT MATERIAL Oryx Additive, Inc. (US) 2024-10-16 EP claimed
WO-2023131803-A1 LYOPHILISED NUCLEIC ACID AMPLIFICATION REACTION COMPOSITION IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-07-13 WO claimed
WO-2023108087-A1 METHOD, APPARATUS, AND SYSTEM FOR SUPPORT MATERIAL REMOVAL FROM A 3D-PRINTED OBJECT ORYX ADDITIVE, INC. (US) 2023-06-15 WO claimed
WO-2023108088-A1 ECO-FRIENDLY METHOD, APPARATUS, AND SYSTEM FOR PRECIPITATION AND COLLECTION OF DISSOLVED SUPPORT MATERIAL ORYX ADDITIVE, INC. (US) 2023-06-15 WO claimed
US-20090157025-A1 Wetness Sensors KIMBERLY-CLARK WORLDWIDE, INC. (US) 2009-06-18 US claimed
WO-2009033135-A1 UNIVERSAL DRINKING ADAPTER FOR BEVERAGE BOTTLES TO ALLOW FOR LIQUID CONSUMPTION AND DEVICES AND KITS FOR DETERMINING SMALL MOLECULES, METAL IONS, ENDOTOXINS, AND BACTERIA FOUND IN MILK, AND METHODS OF USE THEREOF SUREMILK, LLC. (US) 2009-03-12 WO claimed
US-20080244837-A1 Cosmetic article and process for dry dyeing keratin materials L'OREAL S.A. (FR) 2008-10-09 US claimed
EP-1964539-A1 Cosmetic article for dyeing dry hair, its use, method of implementing said article L'Oréal (FR) 2008-09-03 EP claimed
US-20080148496-A1 Dyeing of in Particular Human Keratin Materials by Dry Thermal Transfer of a Direct Dye, Composition Comprising the Said Dye and Its Method of Preparation L'OREAL S.A. (FR) 2008-06-26 US claimed
US-20060173058-A1 Kcnq channel modulating compounds and their pharmaceutical use NEUROSEARCH A/S (DK) 2006-08-03 US claimed
EP-1603858-A2 KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE NeuroSearch A/S (DK) 2005-12-14 EP claimed
WO-2004080377-A2 KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE NEUROSEARCH A/S (DK) 2004-09-23 WO claimed
US-20030087451-A1 Acid test kit MAINSTREAM ENGINEERING CORP. 2003-05-08 US claimed
WO-1996033394-A1 ACID TEST KIT MAINSTREAM ENGINEERING CORPORATION (US) 1996-10-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080244837-A1 Cosmetic article and process for dry dyeing keratin materials KRT18, CUTA, DSG1 TDP1 3293/4885ALDH1A1 844/4885SMN1; SMN2 4813/4885
US-20060173058-A1 Kcnq channel modulating compounds and their pharmaceutical use KCNQ1, KCNQ2, KCNQ5 TDP1 4573/4885ALDH1A1 4394/4885SMN1; SMN2 2692/4885
US-20080148496-A1 Dyeing of in Particular Human Keratin Materials by Dry Thermal Transfer of a Direct Dye, Composition Comprising the Said Dye and Its Method of Preparation KRT18, IK, DSG1 TDP1 3318/4885ALDH1A1 911/4885SMN1; SMN2 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.